Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $21,520.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $5.38, for a total transaction of $21,520.00. Following the completion of the transaction, the director now owns 64,334 shares of the company’s stock, valued at $346,116.92. This represents a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mark Alvino also recently made the following trade(s):

• On Tuesday, January 21st, Mark Alvino sold 4,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.10, for a total transaction of $20,400.00.

Abeona Therapeutics Trading Up 1.3 %

NASDAQ ABEO opened at $5.54 on Friday. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a fifty day simple moving average of $5.73 and a two-hundred day simple moving average of $5.72. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a market cap of $240.82 million, a P/E ratio of -2.06 and a beta of 1.46.

Wall Street Analyst Weigh In

ABEO has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. Finally, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABEO. Renaissance Technologies LLC increased its holdings in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the period. abrdn plc boosted its position in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the last quarter. Rosalind Advisors Inc. increased its holdings in Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after buying an additional 82,000 shares during the period. GSA Capital Partners LLP raised its position in Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after buying an additional 33,831 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at approximately $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.